LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

LLY

748.04

-0.87%↓

JNJ

177.32

-0.43%↓

ABBV

215.06

-1.48%↓

UNH

348.45

-1.26%↓

AZN

77.6

-2.44%↓

Search

Kura Oncology Inc

Abrir

SetorSaúde

8.15 -0.49

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.09

Máximo

8.22

Indicadores-chave

By Trading Economics

Rendimento

-8.7M

-66M

Vendas

1.2M

15M

Margem de lucro

-432.509

Funcionários

192

EBITDA

-8M

-73M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+189.38% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

159M

707M

Abertura anterior

8.64

Fecho anterior

8.15

Sentimento de Notícias

By Acuity

67%

33%

325 / 371 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

12 de set. de 2025, 22:41 UTC

Grandes Movimentos do Mercado

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 de set. de 2025, 16:04 UTC

Grandes Movimentos do Mercado

Upexi Shares Climb on Solana Gains

14 de set. de 2025, 23:48 UTC

Conversa de Mercado

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 de set. de 2025, 23:41 UTC

Conversa de Mercado

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 de set. de 2025, 23:38 UTC

Conversa de Mercado

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 de set. de 2025, 23:13 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 de set. de 2025, 23:13 UTC

Conversa de Mercado

Global Energy Roundup: Market Talk

14 de set. de 2025, 23:13 UTC

Conversa de Mercado

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 de set. de 2025, 23:13 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

14 de set. de 2025, 23:04 UTC

Conversa de Mercado

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 de set. de 2025, 08:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

12 de set. de 2025, 20:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

12 de set. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de set. de 2025, 20:09 UTC

Ganhos

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 de set. de 2025, 19:23 UTC

Conversa de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 de set. de 2025, 19:16 UTC

Conversa de Mercado

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 de set. de 2025, 19:03 UTC

Conversa de Mercado

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 de set. de 2025, 18:59 UTC

Conversa de Mercado

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 de set. de 2025, 18:38 UTC

Conversa de Mercado
Ganhos

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 de set. de 2025, 18:33 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 de set. de 2025, 18:22 UTC

Conversa de Mercado

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 de set. de 2025, 16:56 UTC

Conversa de Mercado

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 de set. de 2025, 16:22 UTC

Ganhos

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 de set. de 2025, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

12 de set. de 2025, 16:19 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 de set. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

12 de set. de 2025, 16:11 UTC

Ganhos

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 de set. de 2025, 15:37 UTC

Conversa de Mercado

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 de set. de 2025, 15:22 UTC

Conversa de Mercado

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 de set. de 2025, 15:07 UTC

Aquisições, Fusões, Aquisições de Empresas

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

189.38% parte superior

Previsão para 12 meses

Média 23.7 USD  189.38%

Máximo 40 USD

Mínimo 7.95 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

11

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

5.575 / 6.6Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

325 / 371 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Baixa

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.
help-icon Live chat